Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Blood (2023) 142 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2023-173873

Published: 2023

Journal Articles

A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to Methotrexate and Tacrolimus

Divya Koura, James Mirocha, Kaitlyn C Dykes, Ayad Hamdan, Aaron Goodman, Tiffany N Tanaka, Carolyn M. Mulroney, Caitlin L. Costello, James K. Mangan, Edward D. Ball, Ah-Reum Jeong, Joseph Maroge, Michelle Padilla, Dimitrios Tzachanis

Blood (2023) 142 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2023-173906

Published: 2023

Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blood (2022) 140 (21): 2248–2260.

https://doi.org/10.1182/blood.2022015478

Published: 2022

Includes: Supplemental data

Journal Articles

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Anupama Kumar, Aaron S Rosenberg, Michelle Padilla, Nina Shah, Lindsey Sirianni, Lin Liu, Yuwei Cheng, Emily Pittman, Dimitrios Tzachanis, Sarah Larson, Carolyn Mulroney, Edward D. Ball, Caitlin Costello

Blood (2022) 140 (Supplement 1): 4436–4437.

https://doi.org/10.1182/blood-2022-169838

Published: 2022

Journal Articles

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Blood (2022) 140 (Supplement 1): 3158–3161.

https://doi.org/10.1182/blood-2022-158248

Published: 2022

Journal Articles

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Blood (2022) 140 (Supplement 1): 1716–1719.

https://doi.org/10.1182/blood-2022-157326

Published: 2022

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Blood (2022) 140 (Supplement 1): 10399–10401.

https://doi.org/10.1182/blood-2022-156117

Published: 2022

Journal Articles

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Blood (2021) 138 (Supplement 1): 430.

https://doi.org/10.1182/blood-2021-147598

Published: 2021

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Blood (2021) 138 (Supplement 1): 2832.

https://doi.org/10.1182/blood-2021-147403

Published: 2021

Journal Articles

A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care

Divya Koura, Dimitrios Tzachanis, Edward D. Ball, Caitlin Costello, Aaron M Goodman, James K. Mangan, Carolyn Mulroney, Joseph Maroge, Michelle Padilla, Peggy Breslin, Jodi Garrett, Kimberly McConnell

Blood (2021) 138 (Supplement 1): 1816.

https://doi.org/10.1182/blood-2021-145824

Published: 2021

Journal Articles

Response to CAR-T Therapy Can be Monitored Using Genome-Wide Sequencing of Cell-Free DNA in Patients with DLBCL

Aaron M Goodman, MD, Kimberly A Holden, Ah-Reum Jeong, MD, Lisa Kim, Kerry D Fitzgerald, PhD, Eyad Almasri, PhD, Graham McLennan, Marcia Eisenberg, PhD, Amin H Jahromi, Carl Hoh, Michael Hurley, Carolyn Mulroney, MD, Dimitrios Tzachanis, MD PhD, Edward D. Ball, MD, Taylor J Jensen, PhD BS, Razelle Kurzrock, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-141010

Published: 2020

Journal Articles

Outcomes of Patients Requiring ICU Admission after CD19 Directed CAR T-Cells

Erica Lin, MD, Ah-Reum Jeong, MD, Michael Hurley, Robert L Owens, MD, Dimitrios Tzachanis, MD PhD, Aaron M Goodman, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-140211

Published: 2020

Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-135818

Published: 2020

Journal Articles

Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML

Huan-You Wang, Dimitrios Tzachanis

Blood (2020) 136 (9): 1112.

https://doi.org/10.1182/blood.2020006326

Published: 2020

Journal Articles

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Marc Schwartz, MD, Lloyd E. Damon, MD, Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD PhD, Gary J. Schiller, MD, Jesika Reiner, MPH, Matthew J. Wieduwilt, MD PhD

Blood (2019) 134 (Supplement_1): 3880.

https://doi.org/10.1182/blood-2019-131061

Published: 2019

Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 1755.

https://doi.org/10.1182/blood-2019-131498

Published: 2019

Journal Articles

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD

Blood (2018) 132 (Supplement 1): 4018.

https://doi.org/10.1182/blood-2018-99-117469

Published: 2018

Journal Articles

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data

Richard T. Maziarz, MD, John Edwards, MD, James Essell, MD, Cesar Freytes, MD, Chatchada Karanes, Ayman Saad, MD, Dimitrios Tzachanis, MD PhD, Monica Diaz, Amanda Medcalf, Chris Storgard, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 2167.

https://doi.org/10.1182/blood-2018-99-115088

Published: 2018

Journal Articles

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood (2018) 131 (25): 2836–2845.

https://doi.org/10.1182/blood-2017-05-780239

Published: 2018

Includes: Supplemental data

Journal Articles

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Richard Maziarz, MD, John Edwards, MD, James Essell, MD, Cesar Freytes, MD, Chatchada Karanes, MD, Ayman Saad, MD, Dimitrios Tzachanis, MD PhD, Monica Diaz, Amanda Medcalf, Daniel Fremgen, Chris Storgard, MD, Abhinav Deol, MD

Blood (2017) 130 (Supplement 1): 4498.

https://doi.org/10.1182/blood.V130.Suppl_1.4498.4498

Published: 2017

NARROW

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to Methotrexate and Tacrolimus

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care

Response to CAR-T Therapy Can be Monitored Using Genome-Wide Sequencing of Cell-Free DNA in Patients with DLBCL

Outcomes of Patients Requiring ICU Admission after CD19 Directed CAR T-Cells

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only